GO:0038183 bile acid signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038183 (bile acid signaling pathway) describes the molecular events triggered when bile acids bind their receptors, leading to downstream cellular responses such as transcriptional regulation.
• The two principal bile acid receptors are the nuclear receptor FXR (NR1H4) and the G protein-coupled receptor TGR5 (GPBAR1), which together mediate metabolic, inflammatory, and immune effects.
• Bile acid signaling is central to whole-body metabolic homeostasis, including glucose and lipid metabolism, energy expenditure, and gut-liver crosstalk.
• Dysregulated bile acid signaling contributes to cholestatic liver diseases, fatty liver disease, inflammatory bowel disease, and gastrointestinal cancers.
• FXR activation induces FGF15/19, which feeds back to repress bile acid synthesis via CYP7A1, forming a classic negative feedback loop.
• CRISPR-based knockout, knock-in, and overexpression models are essential for dissecting causal roles of bile acid signaling components in disease.
Description
Bile acids were historically viewed solely as detergents that facilitate intestinal lipid absorption. However, research over the past two decades has established that bile acids are also potent signaling molecules that activate specific receptors to control gene expression and cellular physiology. The Gene Ontology term GO:0038183, bile acid signaling pathway, captures the series of molecular signals initiated by bile acid binding to its receptor and ending with regulation of a downstream cellular process, such as transcription. This process is fundamental to metabolic integration, influencing not only bile acid synthesis and enterohepatic circulation but also glucose homeostasis, energy expenditure, and immune responses. Understanding bile acid signaling is critical for researchers in hepatology, gastroenterology, endocrinology, and oncology because perturbations in this pathway are linked to prevalent human diseases, including non-alcoholic fatty liver disease, cholestasis, inflammatory bowel disease, and colorectal cancer. The pathway involves a sophisticated network of nuclear and membrane receptors, transporters, and feedback loops that maintain metabolic balance. Consequently, GO:0038183 serves as a conceptual hub for studying how bile acids act as hormones and how their signaling can be therapeutically targeted. This article provides a research-grade overview of the bile acid signaling pathway, covering its definition, molecular mechanisms, key genes, disease associations, and state-of-the-art methods for experimental investigation, including CRISPR-based genome editing. All statements are grounded in authoritative QuickGO annotation and peer-reviewed literature.
bile acid signaling pathway At A Glance
| GO ID | GO:0038183 |
|---|---|
| GO term | bile acid signaling pathway |
| Ontology | biological_process |
| Synonym | none |
| Major function | Signal transduction triggered by bile acid binding to receptors, leading to regulation of downstream cellular processes such as transcription |
| Key receptors | FXR (NR1H4), TGR5 (GPBAR1), and other bile acid-responsive receptors |
| Primary ligands | Bile acids (e.g., cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid) |
| Downstream effects | Regulation of bile acid synthesis, lipid and glucose metabolism, inflammation, and energy homeostasis |
What Is GO:0038183?
The bile acid signaling pathway (GO:0038183) is defined as the series of molecular signals initiated by bile acid binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription. In practice, this encompasses the binding of bile acids such as cholic acid or chenodeoxycholic acid to receptors like FXR and TGR5, the subsequent intracellular signal transduction events, and the ultimate changes in gene expression or cellular behavior.
Why Is bile acid signaling pathway Important in Cell Biology?
GO:0038183 is important because bile acid signaling acts as a master regulator of metabolic and immune homeostasis, and its dysfunction is implicated in a wide range of human diseases, from cholestasis and fatty liver disease to diabetes, inflammatory bowel disease, and cancer. Understanding this pathway provides mechanistic insights into how the body integrates nutrient sensing with gene expression, and it offers multiple druggable targets, such as FXR and TGR5, for therapeutic intervention.
• Controls bile acid synthesis through negative feedback regulation of CYP7A1 via FXR-FGF15/19 axis.
• Regulates lipid and glucose metabolism, influencing insulin sensitivity and energy expenditure.
• Modulates inflammatory responses in the gut and liver, affecting diseases like colitis and hepatitis.
• Influences gut microbiota composition and function through bile acid-microbiota crosstalk.
• Plays a role in gastrointestinal carcinogenesis, including colorectal and liver cancers.
• Provides therapeutic targets for cholestatic liver diseases, NAFLD, and metabolic syndrome.
• Mediates pruritus and other symptoms in cholestasis via TGR5 signaling.
• Is essential for enterohepatic circulation and whole-body metabolic homeostasis.
• Serves as a paradigm for nuclear receptor and GPCR signaling integration.
• Enables research on personalized medicine based on bile acid profiles and receptor polymorphisms.
What Happens During bile acid signaling pathway?
Bile acid synthesis and release
In simple terms: The body makes bile acids from cholesterol and releases them to help digest fats, but these molecules also act as signals.
Bile acids are synthesized from cholesterol primarily in the liver through classical and alternative pathways, with CYP7A1 as the rate-limiting enzyme. After synthesis, they are conjugated and secreted into bile, then released into the intestine upon feeding. This release is the first step that allows bile acids to interact with receptors in the gut and liver, initiating signaling.
Receptor binding and activation
In simple terms: Bile acids act like keys that fit into specific locks (receptors) on cells, turning on signals inside.
Bile acids bind to and activate specific receptors, most notably the nuclear receptor FXR (NR1H4) and the membrane G protein-coupled receptor TGR5 (GPBAR1). FXR is highly expressed in liver, intestine, and kidney, while TGR5 is found in various tissues including enteroendocrine cells, macrophages, and muscle. Binding of bile acids to FXR induces conformational changes that promote heterodimerization with RXR and recruitment of coactivators, leading to transcriptional regulation. TGR5 activation triggers G protein-mediated signaling, including cAMP production and downstream kinase cascades.
Intracellular signal transduction
In simple terms: Once the receptor is activated, a chain of molecular events relays the signal to the cell's command center.
FXR activation leads to transcriptional regulation of target genes involved in bile acid homeostasis, lipid metabolism, and inflammation. Key targets include SHP (NR0B2), which inhibits CYP7A1 transcription, and FGF19 (FGF15 in mice), which acts as a hormone to repress CYP7A1 in the liver. TGR5 signaling activates adenylate cyclase, increasing cAMP and activating PKA, which can modulate gene expression and cellular metabolism. These pathways also crosstalk with other signaling cascades, such as MAPK and PI3K/AKT.
Regulation of downstream cellular processes
In simple terms: The signal ultimately changes how cells behave, such as altering which genes are turned on or off.
The bile acid signaling pathway culminates in the regulation of downstream cellular processes, including transcription of genes involved in bile acid synthesis, transport, and metabolism. For example, FXR activation induces the expression of OSTα/β and BSEP to enhance bile acid efflux and reduce intracellular bile acid levels. It also suppresses inflammatory gene expression by inhibiting NF-κB. TGR5 activation promotes GLP-1 secretion from enteroendocrine L cells, improving glucose homeostasis. Thus, the pathway integrates metabolic and immune responses.
Feedback and crosstalk with microbiota
In simple terms: The signals loop back to control bile acid production, and gut bacteria also influence this process.
A critical feature of bile acid signaling is the negative feedback loop: FXR activation in the intestine induces FGF15/19, which travels to the liver and represses CYP7A1, reducing bile acid synthesis. Additionally, gut microbiota modify bile acids through deconjugation, dehydroxylation, and epimerization, generating secondary bile acids that have distinct signaling properties. This crosstalk between bile acids and microbiota shapes host metabolism and immunity.
Key Genes Involved in GO:0038183 bile acid signaling pathway
The following genes encode key components of the bile acid signaling pathway, including receptors, enzymes, transporters, and downstream effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR1H4 (FXR) | Nuclear receptor activated by bile acids; regulates transcription of genes in bile acid, lipid, and glucose metabolism | Central to bile acid feedback, NAFLD, cholestasis; target for therapeutic agonists |
| GPBAR1 (TGR5) | G protein-coupled receptor for bile acids; mediates cAMP signaling, energy expenditure, and GLP-1 secretion | Implicated in metabolic diseases, inflammation, and pruritus |
| CYP7A1 | Rate-limiting enzyme in classical bile acid synthesis | Key feedback target; dysregulation leads to cholestasis and gallstones |
| CYP8B1 | Enzyme in alternative bile acid synthesis pathway | Determines bile acid pool composition; linked to metabolic disorders |
| FGF19 (FGF15 in mice) | Intestinal hormone induced by FXR; represses CYP7A1 in liver | Critical for bile acid feedback; involved in liver regeneration and cancer |
| NR0B2 (SHP) | Orphan nuclear receptor induced by FXR; inhibits CYP7A1 and other genes | Mediates negative feedback; role in metabolic regulation |
| ABCB11 (BSEP) | Bile salt export pump; transports bile acids from hepatocytes into bile | Mutations cause progressive familial intrahepatic cholestasis |
| SLC10A1 (NTCP) | Sodium-taurocholate cotransporting polypeptide; mediates hepatic bile acid uptake | Entry receptor for hepatitis B virus; target for cholestasis |
| SLC10A2 (ASBT) | Apical sodium-dependent bile acid transporter in ileum | Regulates intestinal bile acid absorption; target for diarrhea and cholestasis |
| SLCO1B1/1B3 | Organic anion transporting polypeptides; mediate hepatic uptake of bile acids | Influence bile acid clearance and drug interactions |
| AKR1D1 | Enzyme in bile acid synthesis; catalyzes 5β-reduction | Deficiency causes bile acid synthesis defects |
| CYP27A1 | Sterol 27-hydroxylase; initiates alternative bile acid synthesis | Mutations cause cerebrotendinous xanthomatosis |
| VDR | Vitamin D receptor; activated by secondary bile acids like LCA | Mediates bile acid detoxification and immune regulation |
| PXR (NR1I2) | Pregnane X receptor; activated by bile acids and xenobiotics | Regulates bile acid detoxification and drug metabolism |
| CAR (NR1I3) | Constitutive androstane receptor; regulates bile acid metabolism | Involved in bile acid homeostasis and hepatoprotection |
| GLP1 | Glucagon-like peptide-1; secreted upon TGR5 activation | Links bile acid signaling to glucose homeostasis |
| IL-6 | Cytokine modulated by bile acid signaling | Mediates inflammatory crosstalk in liver and gut |
| TNF-α | Pro-inflammatory cytokine regulated by FXR and TGR5 | Involved in bile acid-associated inflammation |
How Is bile acid signaling pathway Regulated?
Bile acid signaling is tightly regulated at multiple levels. The FXR-FGF15/19 axis provides a negative feedback loop that suppresses CYP7A1 transcription in the liver, thereby controlling bile acid synthesis. Additionally, FXR induces SHP, which inhibits LRH-1 and HNF4α, further repressing CYP7A1. TGR5 signaling is regulated by receptor desensitization and internalization, as well as by crosstalk with other GPCR pathways. Post-translational modifications of FXR, such as phosphorylation and acetylation, modulate its transcriptional activity. Furthermore, bile acid transporters and microbiota composition influence the availability of bile acids for receptor activation, adding another layer of regulation.
bile acid signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NR1H4 (FXR) | Cholestasis, NAFLD, metabolic syndrome | Liver-specific FXR knockout mice; FXR point-mutation models |
| GPBAR1 (TGR5) | Obesity, diabetes, inflammation | TGR5 knockout mice; TGR5 overexpression in enteroendocrine cells |
| ABCB11 (BSEP) | Progressive familial intrahepatic cholestasis | BSEP knockout mice; patient-derived iPSC hepatocytes |
| FGF19 | Bile acid diarrhea, liver cancer | FGF19 transgenic mice; FGF19 knock-in models |
| CYP7A1 | Gallstones, hypercholesterolemia | CYP7A1 knockout mice; liver-specific overexpression |
Cholestatic liver diseases
Impaired bile acid signaling contributes to cholestasis, a condition characterized by bile flow obstruction and accumulation of toxic bile acids in the liver. Mutations in ABCB11 (BSEP) and ATP8B1 cause progressive familial intrahepatic cholestasis, while dysregulation of FXR and TGR5 signaling exacerbates liver injury. Therapeutic targeting of FXR with agonists such as obeticholic acid has shown efficacy in primary biliary cholangitis.
Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome
Bile acid signaling influences lipid and glucose metabolism, and its dysregulation is linked to NAFLD, insulin resistance, and obesity. FXR activation reduces hepatic lipogenesis and improves insulin sensitivity, while TGR5 activation increases energy expenditure in brown adipose tissue. Genetic variants in NR1H4 and GPBAR1 have been associated with metabolic traits.
Inflammatory bowel disease and gastrointestinal cancers
Bile acid signaling modulates intestinal inflammation and carcinogenesis. FXR deficiency leads to increased intestinal permeability and inflammation, promoting colitis-associated cancer. Secondary bile acids such as deoxycholic acid can activate TGR5 and VDR, influencing cell proliferation and apoptosis. Dysbiosis of gut microbiota alters bile acid profiles, contributing to colorectal cancer risk.
Metabolic and immune homeostasis
Beyond the liver and gut, bile acid signaling regulates whole-body metabolic and immunological homeostasis. TGR5 activation in macrophages reduces inflammation, while FXR signaling in adipose tissue affects adipokine secretion. These pleiotropic effects make bile acid receptors attractive targets for treating metabolic and inflammatory diseases.
From bile acid signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FXR alter bile acid pool and liver injury? | FXR knockout mouse (germline or liver-specific) |
| How does a point mutation in GPBAR1 affect TGR5 signaling? | CRISPR knock-in of point mutation in GPBAR1 in cell lines or mice |
| What is the effect of FGF19 overexpression on bile acid synthesis? | Transgenic FGF19 overexpression mouse or AAV-mediated overexpression |
| Can a tagged FXR be used to map genomic binding sites? | Knock-in of epitope-tagged FXR (e.g., FLAG) for ChIP-seq |
| Does intestinal-specific TGR5 activation improve glucose tolerance? | Intestine-specific TGR5 transgenic or knockout mice |
| What is the role of CYP7A1 in cholesterol gallstone formation? | CYP7A1 knockout and overexpression mouse models |
How to Study the bile acid signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify FXR/TGR5 target genes and pathways |
| ChIP-seq | Genome-wide binding sites of receptors | Map FXR binding and enhancer activity |
| Metabolomics (LC-MS) | Bile acid species and concentrations | Quantify bile acid pool changes in disease models |
| CRISPR knockout screening | Gene essentiality and pathway regulators | Discover novel modulators of bile acid signaling |
| Reporter assays | Transcriptional activity of FXR or TGR5 | Screen for agonists/antagonists and test mutations |
| cAMP assay | TGR5-mediated G protein signaling | Measure TGR5 activation by bile acids |
| Western blot | Protein expression and phosphorylation | Assess FXR/TGR5 protein levels and signaling |
| Immunohistochemistry | Tissue localization of receptors | Study expression patterns in liver and intestine |
Transcriptomic profiling (RNA-seq)
RNA sequencing is widely used to measure global changes in gene expression upon bile acid receptor activation or genetic manipulation. For example, FXR activation alters the expression of genes involved in bile acid synthesis, transport, and inflammation. RNA-seq can identify novel FXR or TGR5 target genes and reveal pathway crosstalk.
Chromatin immunoprecipitation sequencing (ChIP-seq)
ChIP-seq using antibodies against FXR or TGR5 can map genome-wide binding sites and identify direct target genes. This approach has been instrumental in defining FXR response elements and cofactor recruitment. Combining ChIP-seq with RNA-seq provides a comprehensive view of transcriptional regulation by bile acid signaling.
Metabolomics and bile acid profiling
Mass spectrometry-based metabolomics quantifies bile acid species in tissues, serum, and feces. This method reveals changes in bile acid pool composition and synthesis rates in response to genetic or pharmacological interventions. It is essential for understanding how bile acid signaling feedback regulates metabolism.
CRISPR screening and functional genomics
Pooled CRISPR knockout screens can identify genes that modulate bile acid signaling or sensitivity. For instance, screens in cell lines treated with bile acids or FXR agonists can uncover novel regulators of the pathway. Such functional genomics approaches accelerate target discovery and validation.
How CRISPR Can Be Used to Study GO:0038183 bile acid signaling pathway
Knockout
CRISPR-Cas9 knockout of genes such as NR1H4 (FXR) or GPBAR1 (TGR5) in cell lines or animal models is a powerful approach to study loss-of-function phenotypes. For example, FXR knockout mice display elevated bile acid synthesis and liver injury, confirming its role in feedback regulation. Knockout of CYP7A1 in mice leads to altered cholesterol metabolism and gallstone susceptibility.
Point Mutation
CRISPR-mediated point mutations can model disease-associated variants or disrupt specific functional domains. For instance, introducing a point mutation in the ligand-binding domain of FXR can abrogate bile acid binding, allowing dissection of receptor-specific effects. Similarly, point mutations in TGR5 can uncouple G protein signaling from β-arrestin recruitment.
Knock-in
Knock-in of reporter genes or epitope tags (e.g., FLAG, HA) into endogenous loci enables tracking of receptor expression and localization. Knock-in of human FGF19 into the mouse Fgf15 locus can humanize the feedback axis for drug testing. Additionally, knock-in of disease-relevant mutations (e.g., in ABCB11) creates models for cholestasis.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of genes like FGF19 or TGR5 can enhance signaling and study gain-of-function effects. Overexpression of FGF19 in mice reduces bile acid synthesis and protects against cholestasis. TGR5 overexpression in enteroendocrine cells increases GLP-1 secretion and improves glucose tolerance.
How EDITGENE Supports bile acid signaling pathway Research
Researchers studying bile acid signaling pathway-related genes often need to determine whether a candidate gene is causally involved in metabolic or inflammatory phenotypes. This requires precise genetic manipulation, such as knockout, point mutation, knock-in, or overexpression, to establish direct links between gene function and cellular outcomes. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such investigations.
Contact EDITGENE today to design your custom CRISPR model for bile acid signaling pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NR1H4 Knockout HEK293 Cell Line | EDJ-KQ13735 | Human | 9971 | Details Get a Quote |
| NR1H4 Knockout Hep 3B2.1-7 Cell Line | EDJ-KZ373 | Human | 9971 | Details Get a Quote |
| NR1H4 Knockout Huh-7 Cell Line | EDJ-KZ374 | Human | 9971 | Details Get a Quote |
| NR1H4 Knockout HeLa Cell Line | EDJ-KQ55290 | Human | 9971 | Details Get a Quote |
| NR1H4 Knockout A-549 Cell Line | EDJ-KQ63772 | Human | 9971 | Details Get a Quote |
| NR1H4 Knockout HCT 116 Cell Line | EDJ-KQ72231 | Human | 9971 | Details Get a Quote |
Frequently Asked Questions About bile acid signaling pathway
What is GO:0038183 bile acid signaling pathway?
GO:0038183 is a Gene Ontology biological process term defined as the series of molecular signals initiated by bile acid binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.
What genes are involved in bile acid signaling pathway?
Key genes include NR1H4 (FXR), GPBAR1 (TGR5), CYP7A1, FGF19, NR0B2 (SHP), ABCB11 (BSEP), and SLC10A1 (NTCP), among others.
How does bile acid signaling regulate metabolism?
Bile acid signaling controls lipid and glucose metabolism, energy expenditure, and bile acid synthesis through receptors like FXR and TGR5, which regulate gene expression and hormone secretion.
What diseases are associated with bile acid signaling dysfunction?
Dysregulation is linked to cholestasis, NAFLD, inflammatory bowel disease, colorectal cancer, and metabolic syndrome.
What is the role of FXR in bile acid signaling?
FXR is a nuclear receptor that, upon bile acid binding, induces target genes such as SHP and FGF19 to inhibit bile acid synthesis and modulate lipid and glucose metabolism.
How is TGR5 involved in bile acid signaling?
TGR5 is a G protein-coupled receptor that mediates rapid signaling via cAMP, influencing energy expenditure, GLP-1 secretion, and inflammation.
What experimental models are used to study bile acid signaling?
Common models include knockout and transgenic mice, CRISPR-edited cell lines, and patient-derived organoids, combined with RNA-seq, ChIP-seq, and metabolomics.
How can CRISPR be used to study bile acid signaling?
CRISPR enables knockout, point mutation, knock-in, and overexpression of genes like FXR and TGR5 to dissect their causal roles in disease.
What is the FXR-FGF15/19 feedback loop?
It is a negative feedback mechanism where intestinal FXR activation induces FGF15/19, which travels to the liver and represses CYP7A1, reducing bile acid synthesis.
Why is bile acid signaling important for drug discovery?
Because it offers druggable targets (e.g., FXR, TGR5) for treating cholestasis, NAFLD, diabetes, and inflammatory diseases.
Conclusion
The bile acid signaling pathway (GO:0038183) represents a critical interface between nutrient sensing, metabolism, and immunity. Its dysregulation underlies prevalent human diseases, making it a fertile ground for both basic and translational research. Advances in CRISPR genome editing and multi-omics technologies are accelerating the discovery of novel pathway components and therapeutic targets. EDITGENE stands ready to support these efforts with tailored cell models and screening services.
References
- 1. Chiang JY. 2013. Bile acid metabolism and signaling.. Compr Physiol 3(3):1191-212 PMID: 23897684
- 2. Jia W et al.. 2018. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.. Nat Rev Gastroenterol Hepatol 15(2):111-128 PMID: 29018272
- 3. Fleishman JS et al.. 2024. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets.. Signal Transduct Target Ther 9(1):97 PMID: 38664391
- 4. Chiang JYL et al.. 2020. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.. Am J Physiol Gastrointest Liver Physiol 318(3):G554-G573 PMID: 31984784
- 5. Li T et al.. 2014. Bile acid signaling in metabolic disease and drug therapy.. Pharmacol Rev 66(4):948-83 PMID: 25073467
- 6. Jia W et al.. 2024. Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis.. Sci China Life Sci 67(5):865-878 PMID: 37515688
- 7. Di Ciaula A et al.. 2017. Bile Acid Physiology.. Ann Hepatol 16(Suppl. 1: s3-105.):s4-s14 PMID: 29080336
- 8. Katafuchi T et al.. 2022. Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis.. Int J Mol Sci 23(11) PMID: 35682726
